Singapur - anglès - HSA (Health Sciences Authority)

novem healthcare pte ltd - tranexamic acid - injection, solution - tranexamic acid 100 mg/ml

Canadà - anglès - Health Canada

homeocan inc. - rumex obtusifolius - tablet - 1ch - rumex obtusifolius 1ch - homeopathic products

Canadà - anglès - Health Canada

homeocan inc. - rumex acetosa - globules - 1x - rumex acetosa 1x - homeopathic products

Canadà - anglès - Health Canada

homeocan inc. - rumex obtusifolius - globules - 1x - rumex obtusifolius 1x - homeopathic products

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; hydrochloric acid; sodium hydroxide; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 10 ic/ml (rumex acetosa pollen extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (rumex acetosa pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Israel - anglès - Ministry of Health

tec-o-pharm-libra ltd - tranexamic acid - solution for injection - tranexamic acid 500 mg / 5 ml - tranexamic acid - general fibrinolysis. this may occur in prostatic and pancreatic carcinoma following thoracic surgery and other major operative procedures, in obstetrical complications such as abruptio placentae and post-partum hemorrhage, in connection with thrombolytic therapy, and in initial and follow-up treatment following prostatectomy and bladder surgery. prior to, and following, dental surgery in hemophiliacs. epistaxis.

República de Sud-àfrica - anglès - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - solution - 500,0 mg - each 5 ml ampoule contains tranexamic acid 500,0 mg